Four E-prostanoid (EP) receptors, designated EP1, E-2, EP3, and EP4, mediat
e the cellular effects of prostaglandin E-2 (PGE(2)). The present studies p
harmacologically characterize the vasopressor and vasodepressor EP receptor
s in wild-type mice (EP2+/+ mice) and mice with targeted disruption of the
EP, receptor (EP2-/- mice). Mean arterial pressure (MAP) was measured via a
carotid artery catheter in anesthetized male mice. Intravenous infusion of
PGE, decreased MAP in EP2+/+ mice but increased MAP in EP2-/- mice. Infusi
on of EP3-selective agonists, including MB28767, SC46275, and sulprostone,
increased MAP in both EP2+/+ and EP2-/- mice, Pretreatment with SC46275 des
ensitized mice to the subsequent presser effect of sulprostone, but the vas
odepressor effect of PGE, in EP2+/+ mice remained intact. Although PGE(2) a
lone increased MAP in EP2-/- mice, prior desensitization of the presser eff
ect with SC46275 allowed a residual vasodepressor effect of PGE(2) to be se
en in the EP2-/- mice. An EP4-selective agonist (prostaglandin E-1-OH) func
tioned also as a vasodepressor in both EP2-/- and EP2+/+ mice. High levels
of EP3 receptor mRNA were detected in mouse aortas and rabbit preglomerular
arterioles by nuclease protection, with lower expressions of EP1, EP2, and
EP4 mRNA. The findings suggest that combined vasodepressor effects of EP2
and EP4 receptors normally dominate, accounting for the depressor effects o
f PGE(2). In contrast, in EP2-/- mice, EP4 receptor activity alone is insuf
ficient to overcome the EP3 vasopressor effect. These findings suggest that
a balance between presser and depressor PGE(2) receptors determines its ne
t effect on arterial pressure and that these receptors may be important the
rapeutic targets.